Practice

Indian Providers Boast Interchangeability for Insulin Biosimilars Despite Debates in the US

August 5th 2024

By Skylar Jeremias

Article

The introduction of biosimilar insulins, particularly insulin glargine, is crucial for improving insulin accessibility and adherence among patients with diabetes in India, according to a study evaluating expert opinions from Indian doctors.

Budget Impact Analysis of Biosimilar Natalizumab in the US

July 25th 2024

By Edward Li, PharmD, MPH

Article

Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.

Biosimilars in America: Overcoming Barriers and Maximizing Impact

July 21st 2024

By Skylar Jeremias

Podcast

Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.

Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction

July 20th 2024

By Deana Ferreri, PhD

Article

Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.

Biosimilar DMARDs Offer Cost-Effective Option for Patients With RA After Failed Methotrexate Treatment

July 15th 2024

By Cameron Santoro

Article

Economic evaluations of biosimilar disease-modifying antirheumatic drugs (DMARDs) suggest cost-effectiveness for patients with rheumatoid arthritis (RA) who did not respond well to methotrexate, potentially improving patient outcomes and health care affordability.

Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer

July 9th 2024

By Skylar Jeremias

Article

A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.

EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions

June 27th 2024

By Skylar Jeremias

Article

Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.

Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching

June 26th 2024

By Skylar Jeremias

Article

Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.

Authors Spotlight Long-Term Solutions to Ensure Biosimilar Market Sustainability

June 25th 2024

By Skylar Jeremias

Article

Authors of a commentary piece propose solutions to sustainability issues for biosimilar markets and shed light on common sustainability challenges global markets face.

Overcoming Economic, Noneconomic Barriers to Biosimilar Adoption in Oncology

June 20th 2024

By Skylar Jeremias

Article

The broader adoption of biosimilar drugs has the potential to significantly reduce cancer care costs and improve patient access to more affordable treatments, benefiting both patients and payers. However, a recent review highlights that biosimilar uptake has been hindered by various economic, practical, attitudinal, and psychological factors.